Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors

Study summary

The objectives of this study are to explore different dosing levels and schedules of entinostat in combination with pembrolizumab in patients with advanced solid tumors, in terms of safety, tolerability, pharmacokinetics (PK), impact on immune correlatives, and efficacy

Ask AI to explain this study

Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedEntinostat and Pembrolizumab

The study team can explain what participation involves.

Who it may be forNeoplasms · Neoplasms, Glandular and Epithelial

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Jan 25, 2022 · Source: ClinicalTrials.gov

Is enrollment open?Completed

Ask the study team to confirm whether enrollment is open.

What kind of study?Phase 1

Interventional

Where is it offered?1 U.S. location

Locations may change over time.

Who runs it?Syndax Pharmaceuticals

Study sponsor

Study overview

What this study is about

Purpose: Treatment
Study type: Interventional
Phase: Phase 1
Sponsor: Syndax Pharmaceuticals
Interventions being studied: Drug: Entinostat; Drug: Pembrolizumab

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Treatment approach

Immunotherapy→

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

1. Completed Study SNDX-275-0140 (NCT02897778) 2. Any AE or toxicity experienced in Study SNDX-275-0140 (NCT02897778) is resolved to less than or equal to Grade 1 3. Continues to meet inclusion criteria for Study SNDX-275-0140 (NCT02897778) at the time of entry into this study

Reasons someone may not be able to joinExclusion criteria

1. Completed Study SNDX-275-0140 (NCT02897778) more than 30 days prior to Cycle 1 Day 1 of this study 2. Continues to meet

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

The START Center for Cancer CareSan Antonio, Texas

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jan 25, 2022. Always confirm current availability with the study team.

View original record ↗